Project Grant K23HD115855
- This $697,256 project grant awarded by the Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), under the Child Health and Human Development Extramural Research program (CFDA 93.865), aims to identify distinct subphenotypes and endotypes in children with sepsis-induced multi-organ dysfunction syndrome (MODS). The study, titled "Discovering Subphenotypes and Endotypes in Pediatric Sepsis-Induced MODS: The DISPENSE Study", will leverage data from two...
- This federal Project Grant award from the National Institute of General Medical Sciences (NIGMS), under the Biomedical Research and Research Training program (CFDA 93.859), provides $179,475 to The Children's Hospital of Philadelphia (CHOP) to conduct research on pediatric sepsis. The key objectives of the project are to define and validate a molecular subphenotyping model that can predict the severity of sepsis in children, and to test the reversibility of immune dysregulation through targeting...
- This Project Grant award of $739,487.00 from the Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), under the Child Health and Human Development Extramural Research program (CFDA 93.865), aims to refine the understanding of immune heterogeneity in pediatric sepsis-induced multiple organ dysfunction syndrome (SIMODS). The key objectives are to: (1) define specific functional immune endotypes and refine the heterogeneity over time in immunosuppressive or...
- This Project Grant award of $186,221 from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research Federal Grant Program (CFDA 93.855), aims to develop personalized therapies for pediatric sepsis. The primary objectives are to augment sepsis phenotypes through the integration of high-frequency physiologic data with electronic health record data, and to retrospectively identify sepsis subtypes that may respond differently to various...
- This Project Grant award of $455,000 from the National Institute of General Medical Sciences (NIGMS) Biomedical Research and Research Training Program (CFDA 93.859) aims to decrease sepsis mortality in the pediatric population. The key products and services to be delivered include: Developing an AI-guided early sepsis identification tool to enable timely diagnosis and treatment. Performing sepsis phenotyping and creating digital twin patient models to predict personalized treatment responses....
- This federal Project Grant award from the Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), under the Child Health and Human Development Extramural Research program (CFDA 93.865), provides $181,438 to The Children's Hospital of Philadelphia (CHOP) to conduct a prospective longitudinal study on neurocognitive outcomes and recovery trajectory for 180 school-aged pediatric sepsis survivors over 12 months. The key objectives are to evaluate the prevalence of...
- This federal Project Grant award of $489,500.00 from the National Institute of Allergy and Infectious Diseases (CFDA 93.855 - Allergy and Infectious Diseases Research) supports research to characterize the role of the ADB2 complement receptor in acute lung injury associated with sepsis. The primary objectives are to: 1) Determine the binding profile of ADB2 to different complement fragments and its contribution to leukocyte binding; and 2) Delineate the mechanism by which ADB2 regulates...
- This Project Grant award from the National Institute of General Medical Sciences (NIGMS), under the Biomedical Research and Research Training program (CFDA 93.859), provides $418,750.00 to The Feinstein Institutes for Medical Research to conduct research on T cell receptor-mediated T cell activation in neonatal and pediatric sepsis. The goal is to gain insight into how T cell memory influences sepsis-associated organ dysfunction, by comparing responses between human neonates with sepsis and...
- This Project Grant award from the National Institute of Allergy and Infectious Diseases (CFDA 93.855 - Allergy and Infectious Diseases Research) provides $721,728 to the Regents of the University of Michigan to conduct research on "Modulation of Pediatric Sepsis by Virus Persistence." The research aims to identify novel biomarkers that can help define sepsis phenotypes and predict patient responses to immunomodulatory therapies. Specifically, the study will investigate how persistent...
- This Project Grant award of $190,163 from the National Institute of Child Health and Human Development (NICHD) under the Child Health and Human Development Extramural Research program (CFDA 93.865) supports the development of the Utah Pediatric Clinical Pharmacology Training Program at the University of Utah. The program aims to train a diverse, highly skilled workforce in pediatric and maternal clinical pharmacology research to address critical knowledge gaps in safe and effective drug dosing...
This federal Project Grant award from the Eunice Kennedy Shriver National Institute of Child Health and Human Development (CFDA 93.865 - Child Health and Human Development Extramural Research) will provide $167,400.00 to the University of Utah to conduct research on optimizing the dosing of the drug anakinra for the treatment of children with sepsis-induced multiple organ dysfunction syndrome (MODS). The key objectives of the research are to: 1) characterize the kinetics of endogenous interleukin-1 receptor antagonist (IL-1RA) in children with sepsis-induced MODS, 2) incorporate relevant drug and population factors into a physiologically-based pharmacokinetic-pharmacodynamic (PBPK-PD) model to predict anakinra disposition and efficacy, and 3) validate the PBPK-PD model using prospective data from the Personalized Immunomodulation in Pediatric Sepsis-induced MODS (PRECISE) clinical trial. This research aims to determine a safe and effective anakinra dosing regimen for treating children with sepsis-induced MODS.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | $167.4k | 9/5/25 |